A phase 2 study of the inhaled pan-JAK inhibitor TD-0903 in severe COVID-19: Part 1

Dave Singh, Maxim Bogus, Valentyn Moskalenko, Robert Lord, Edmund J. Moran, Glenn D. Crater, David L. Bourdet, Nathan D. Pfeifer, Jacky Woo, Elad Kaufman, David A. Lombardi, Emily Y. Weng, Tuan Nguyen, Ashley Woodcock, Brett Haumann, Rajeev Saggar
doi: https://doi.org/10.1101/2021.03.09.21252944

Article usage

Article usage: March 2021 to June 2025

AbstractFullPdf
Mar 2021161728230
Apr 20215225129
May 2021357675
Jun 2021330639
Jul 2021160535
Aug 2021164836
Sep 2021117140
Oct 202192238
Nov 2021111332
Dec 2021118028
Jan 202287820
Feb 202264819
Mar 202263316
Apr 202269015
May 202286521
Jun 2022801975
Jul 202256059
Aug 20225818
Sep 202245111
Oct 2022148112
Nov 202242012
Dec 202234013
Jan 20234319
Feb 20233228
Mar 202336011
Apr 20233418
May 202337113
Jun 202325413
Jul 20231718
Aug 2023311212
Sep 20235849
Oct 20233114
Nov 202387010
Dec 20236717
Jan 20241707
Feb 20243218
Mar 20241615
Apr 202423111
May 20242565
Jun 20242728
Jul 202421415
Aug 2024211517
Sep 202434215
Oct 202414314
Nov 20242429
Dec 202435018
Jan 202518111
Feb 202524612
Mar 2025431120
Apr 202532131
May 202527917
Jun 202530812
Back to top
Posted March 12, 2021.
Download PDF

Supplementary Material

Data/Code
Email
A phase 2 study of the inhaled pan-JAK inhibitor TD-0903 in severe COVID-19: Part 1
Dave Singh, Maxim Bogus, Valentyn Moskalenko, Robert Lord, Edmund J. Moran, Glenn D. Crater, David L. Bourdet, Nathan D. Pfeifer, Jacky Woo, Elad Kaufman, David A. Lombardi, Emily Y. Weng, Tuan Nguyen, Ashley Woodcock, Brett Haumann, Rajeev Saggar
medRxiv 2021.03.09.21252944; doi: https://doi.org/10.1101/2021.03.09.21252944
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area